Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
Date:2/23/2010

of-concept for two of our four clinical programs, with positive results in Phase 2 clinical trials for both LX1031 in IBS and LX4211 in type 2 diabetes," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon.  "We look forward to reporting Phase 2 clinical results from our next two programs, LX2931 for rheumatoid arthritis and LX1032 for carcinoid syndrome."

Key Developments of 2009

  • Lexicon reported positive results from the Phase 2a clinical trial of its drug candidate for non-constipating irritable bowel syndrome (IBS), LX1031, an inhibitor of tryptophan hydroxylase that acts locally to reduce serotonin synthesis in the gastrointestinal tract.  Top-line data demonstrated that t
    '/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
2. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
3. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
4. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
5. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
6. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
7. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
8. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
9. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
10. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
11. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... EDISON, N.J. , Sept. 1, 2015  ContraVir ... focused on the development and commercialization of targeted antiviral ... Rodman & Renshaw 17 th Annual Global Investment ... taking place September 8-10, 2015 at The St. Regis ... James Sapirstein , Chief Executive ...
(Date:9/1/2015)... Poway, CA (PRWEB) , ... September 01, 2015 ... ... Equine Cervical Facet joint disease. , Equine cervical facet joint problems can ... joints gradually enlarge, and can cause impingement of nerve roots or of the ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Business Development, Asia Pacific. In this newly-created position, Gibbs will lead iLab’s business ... of iLab’s suite of tools. This entails not only introducing iLab to potential ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Global Supply Chain ... management and resiliency practitioners with luminaries and thought leaders to advance the professional ... for their innovations and performance excellence. At that time its principle sponsor, ...
Breaking Biology Technology:ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3
... CRY ),a biomaterials, medical device and tissue ... 2008 Cardiac Allograft Symposium at its,corporate headquarters training ... will focus on current clinical outcomes, indications and,surgical ... the CryoValve(R) SG pulmonary human heart valves., ...
... Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today ... controlling interest in Jiangsu,Institute of Microbiology Co., Ltd. ... the People,s Republic of China. JSIM,has several drugs ... its development pipeline. This acquisition is expected to ...
... United,Therapeutics Corporation (Nasdaq: UTHR ) announced today ... results before the open of market,on Thursday, May ... half-hour teleconference on Thursday,May 1, 2008, at 9:00 ... 1-800-603-1777, with international callers dialing 1-706-679-8129.,A rebroadcast of ...
Cached Biology Technology:CryoLife Conducts Surgeons Cardiac Allograft Symposium 2Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition 2
(Date:8/12/2015)... 12, 2015  New research unveiled at Black ... phones to steal users, fingerprints. Information released today ... fingerprint scanners on mobile devices, making the security ... biometrics on mobile devices, HYPR Corp. recently released ... authentication systems with strong cryptographic security. More information ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... 27 SAFC®, a member of the Sigma-Aldrich® Group ... investment program to expand its Lenexa, KS , ... seamless upstream and downstream production of dry powder media and ... designed to better serve the biopharmaceutical industry by creating ,Centers ...
... , April 27 Negotiations broke off early Tuesday morning between ... Professionals (PASNAP) following a 14-hour session.  Talks are expected to resume later today at ... Continued progress was reported, ... , , ...
... MDC ) today announced that its board of directors has declared a regular quarterly ... common stock.  The dividend will be paid on Wednesday, May 26, 2010 to ... , , ... , Since 1972, MDC,s subsidiary ...
Cached Biology News:SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 2SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 3SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 4SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 5M.D.C. Holdings Declares Quarterly Cash Dividend 2
... separation and fractionation of nucleic-acid ... nuclei from cytosolic proteins A ... greatly facilitating study of low-abundance ... acid binding proteins (e.g., transcription ...
... was developed for culturing hybrid cells that ... consists of doubling the amino acids and ... concentrations have been altered as well. This ... liter, which may render it unsuitable for ...
... is an 18 amino acid synthetic peptide whose sequence corresponds to ... peptide is (amino to carboxy terminus): M(1) - A - S ... A - S - P - R - D - A ... peptide may be used for neutralization and control experiments with the ...
... EpiTect Bisulfite Kit enables complete conversion ... less than 6 hours. The highly ... against DNA degradation and a spin-column-based ... fast and reliable results for all ...
Biology Products: